Cystic fibrosis deaths in the United States from 1979 through 1991. An analysis using multiple-cause mortality data

C S Halliburton1, D M Mannino, R S Olney

  • 1Air Pollution and Respiratory Health Branch, Centers for Disease Control and Prevention, Atlanta, Ga, USA.

Insights

Mortality rates for cystic fibrosis declined by 21% between 1979 and 1991, with the median age of death increasing significantly. These trends suggest improved pediatric treatment for cystic fibrosis.

Area of Science:

  • Pulmonology
  • Epidemiology
  • Public Health

Background:

  • Cystic fibrosis (CF) is a genetic disorder affecting multiple organs.
  • Mortality trends in CF provide insights into disease progression and treatment efficacy.

Purpose of the Study:

  • To analyze mortality trends in individuals diagnosed with cystic fibrosis (CF) from 1979 to 1991.
  • To identify changes in age-adjusted mortality rates and median age at death for CF patients.

Main Methods:

  • Utilized death certificate data from the National Center for Health Statistics (NCHS).
  • Analyzed 6,500 death records with a cystic fibrosis diagnosis between 1979 and 1991.
  • Calculated age-adjusted mortality rates and median age of death.

Main Results:

  • Age-adjusted CF mortality rate decreased by 21% (from 2.4 to 1.9 per million).
  • Median age of death increased from 15 (1979) to 23 years (1991).
  • Whites had significantly higher mortality rates compared to Black individuals and other races.

Conclusions:

  • Observed decrease in CF mortality and increase in median age at death suggest improved treatment outcomes.
  • Potential contributing factors include advancements in pediatric care for cystic fibrosis.
  • Changes in death certification practices and diagnostic accuracy may also influence observed trends.
Abstract

Related Concept Videos

Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...